BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21664691)

  • 1. In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
    Gupta A; Le A; Belinka BA; Kachlany SC
    Leuk Res; 2011 Nov; 35(11):1498-505. PubMed ID: 21664691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukotoxin (Leukothera®) targets active leukocyte function antigen-1 (LFA-1) protein and triggers a lysosomal mediated cell death pathway.
    DiFranco KM; Gupta A; Galusha LE; Perez J; Nguyen TK; Fineza CD; Kachlany SC
    J Biol Chem; 2012 May; 287(21):17618-17627. PubMed ID: 22467872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-leukemia activity of a bacterial toxin with natural specificity for LFA-1 on white blood cells.
    Kachlany SC; Schwartz AB; Balashova NV; Hioe CE; Tuen M; Le A; Kaur M; Mei Y; Rao J
    Leuk Res; 2010 Jun; 34(6):777-85. PubMed ID: 19747730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LFA-1-targeting Leukotoxin (LtxA; Leukothera®) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes.
    DiFranco KM; Johnson-Farley N; Bertino JR; Elson D; Vega BA; Belinka BA; Kachlany SC
    Leuk Res; 2015 Jun; 39(6):649-56. PubMed ID: 25850729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells.
    Wang Y; Yang Z; Zhao X
    Toxicol Mech Methods; 2010 Jun; 20(5):234-41. PubMed ID: 20374036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic targeting of leukemia with leukotoxin and chemotherapy.
    Kreitman RJ
    Leuk Res; 2011 Nov; 35(11):1438-9. PubMed ID: 21764132
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
    De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
    Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
    Baran Y; Oztekin C; Bassoy EY
    Cancer Invest; 2010 Jul; 28(6):623-8. PubMed ID: 20307198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukotoxin (LtxA/Leukothera) induces ATP expulsion via pannexin-1 channels and subsequent cell death in malignant lymphocytes.
    Prince DJ; Patel D; Kachlany SC
    Sci Rep; 2021 Sep; 11(1):18086. PubMed ID: 34508147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LukS-PV induces mitochondrial-mediated apoptosis and G0/G1 cell cycle arrest in human acute myeloid leukemia THP-1 cells.
    Bu S; Xie Q; Chang W; Huo X; Chen F; Ma X
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1531-7. PubMed ID: 23702031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine.
    Chow KU; Boehrer S; Geduldig K; Krapohl A; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2001 May; 86(5):485-93. PubMed ID: 11410411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MZ3 induces apoptosis in human leukemia cells.
    Fang L; He Q; Hu Y; Yang B
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):397-405. PubMed ID: 16900371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor-Based Peptides for Inhibition of Leukotoxin Activity.
    Krueger E; Hayes S; Chang EH; Yutuc S; Brown AC
    ACS Infect Dis; 2018 Jul; 4(7):1073-1081. PubMed ID: 29742342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quercetin decreases intracellular GSH content and potentiates the apoptotic action of the antileukemic drug arsenic trioxide in human leukemia cell lines.
    Ramos AM; Aller P
    Biochem Pharmacol; 2008 May; 75(10):1912-23. PubMed ID: 18359480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
    Majlessipour F; Avramis IA; Kwock R; Weinberg KI; Avrami VI
    Anticancer Res; 2002; 22(3):1361-8. PubMed ID: 12168812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of LtxA (Leukotoxin), a Potent New Anti-Inflammatory Agent for the Treatment of Alopecia Areata.
    Kachlany SC
    J Investig Dermatol Symp Proc; 2015 Nov; 17(2):19-22. PubMed ID: 26551939
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Vega BA; Belinka BA; Kachlany SC
    Toxins (Basel); 2019 Aug; 11(9):. PubMed ID: 31454891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.